| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $12.3M | -90.7% |
| SG&A Expense | $42.9M | -11.1% |
| Operating Income | -$65.4M | +67.3% |
| Pre-tax Income | -$58.8M | +69.2% |
| Income Tax | $0 | +100.0% |
| Net Income | -$58.8M | +69.1% |
| EPS (Basic) | -$11.73 | -541.0% |
| EPS (Diluted) | -$11.73 | -541.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $118.3M | +31.3% |
| Short-term Investments | $0 | -100.0% |
| Current Assets | $118.5M | -36.8% |
| Total Assets | $118.5M | -37.9% |
| Current Liabilities | $5.2M | -81.5% |
| Total Liabilities | $5.2M | -88.4% |
| Stockholders' Equity | $113.3M | -22.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$67.7M | +45.6% |
| Investing Cash Flow | $95.0M | +150.1% |
| Financing Cash Flow | $21K | -100.0% |